Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Xicheng Wang, Jianfeng Zhou, Yan Li, Yuping Ge, Yanping Zhou, Chunmei Bai & Lin Shen. (2020) Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study. Clinical Pharmacology: Advances and Applications 12, pages 21-33.
Read now
Read now
Akihito Kawazoe & Kohei Shitara. (2020) Trifluridine/tipiracil for the treatment of metastatic gastric cancer. Expert Review of Gastroenterology & Hepatology 14:2, pages 65-70.
Read now
Read now
Julia Martinez-Perez, M. Carmen Riesco-Martinez & Rocio Garcia-Carbonero. (2018) The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer. Expert Opinion on Drug Safety 17:6, pages 643-650.
Read now
Read now
Yu Sunakawa, Naoki Izawa, Takuro Mizukami, Yoshiki Horie, Mami Hirakawa, Hiroyuki Arai, Takashi Ogura, Takashi Tsuda & Takako Eguchi Nakajima. (2017) Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy. OncoTargets and Therapy 10, pages 4599-4605.
Read now
Read now
Jeevan M Puthiamadathil & Benjamin A Weinberg. (2017) Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil. Cancer Management and Research 9, pages 461-469.
Read now
Read now
Diana L. Hanna & Heinz-Josef Lenz. (2016) Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Review of Clinical Pharmacology 9:8, pages 1091-1108.
Read now
Read now
Yuji Miyamoto, Heinz-Josef Lenz & Hideo Baba. (2016) A novel antimetabolite: TAS-102 for metastatic colorectal cancer. Expert Review of Clinical Pharmacology 9:3, pages 355-365.
Read now
Read now
Lisa Salvatore, Daniele Rossini, Roberto Moretto, Chiara Cremolini, Marta Schirripa, Carlotta Antoniotti, Federica Marmorino, Fotios Loupakis, Alfredo Falcone & Gianluca Masi. (2015) TAS-102 for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy 15:11, pages 1283-1292.
Read now
Read now
Hiroshi Yasui, Giichiro Tsurita & Kohzoh Imai. (2014) DNA synthesis inhibitors for the treatment of gastrointestinal cancer. Expert Opinion on Pharmacotherapy 15:16, pages 2361-2372.
Read now
Read now
Norihiko Suzuki & Masakazu Fukushima. (2010) Simple and Rapid Enzymatic Method for the Synthesis of Single-Strand Oligonucleotides Containing Trifluorothymidine. Nucleosides, Nucleotides & Nucleic Acids 29:11-12, pages 896-904.
Read now
Read now
Articles from other publishers (47)
Becka M. Warfield & Philip Reigan. (2022) Multifunctional role of thymidine phosphorylase in cancer. Trends in Cancer 8:6, pages 482-493.
Crossref
Crossref
Sakti Chakrabarti, Grant Wintheiser, Sri Harsha Tella, Carolyn Oxencis & Amit Mahipal. (2021) TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies. Pharmacology & Therapeutics 224, pages 107823.
Crossref
Crossref
M. Yu. Fedyanin. (2020) Trifluridine / tipiracil (FTd / TPI, TAS-102) in the treatment of patients with metastatic colon cancer: from preclinical experiments to routine clinical practice. Pelvic Surgery and Oncology 10:3-4, pages 11-26.
Crossref
Crossref
Giandomenico Roviello, Sara Fancelli, Marta Rita Gatta Michelet, Giuseppe Aprile, Stefania Nobili, Franco Roviello, Fabio Cianchi, Enrico Mini & Daniele Lavacchi. (2020) TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination. Critical Reviews in Oncology/Hematology 152, pages 102987.
Crossref
Crossref
Sakti Chakrabarti, Tyler J. Zemla, Daniel H. Ahn, Fang-Shu Ou, Briant Fruth, Mitesh J. Borad, Mindy L. Hartgers, Jaclynn Wessling, Rachel L. Walkes, Steven R. Alberts, Robert R. McWilliams, Minetta C. Liu, Lori M. Durgin, Tanios S. Bekaii-Saab & Amit Mahipal. (2020) Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. The Oncologist 25:5, pages 380-e763.
Crossref
Crossref
A. Fernandez Montes, F. Vazquez Rivera, N. Martinez Lago, M. Covela Rúa, A. Cousillas Castiñeiras, P. Gonzalez Villarroel, J. de la Cámara Gómez, J. C. Méndez Méndez, M. Salgado Fernández, S. Candamio Folgar, M. Reboredo López, M. Carmona Campos, E. Gallardo Martín, M. Jorge Fernández, M. L. Pellón Augusto, L. París Bouzas & J. García Gómez. (2019) Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. Clinical and Translational Oncology 22:3, pages 351-359.
Crossref
Crossref
T. Yoshino, J.M. Cleary, E. Van Cutsem, R.J. Mayer, A. Ohtsu, E. Shinozaki, A. Falcone, K. Yamazaki, T. Nishina, R. Garcia-Carbonero, Y. Komatsu, H. Baba, G. Argilés, A. Tsuji, A. Sobrero, K. Yamaguchi, M. Peeters, K. Muro, A. Zaniboni, N. Sugimoto, Y. Shimada, Y. Tsuji, H.S. Hochster, T. Moriwaki, B. Tran, T. Esaki, C. Hamada, T. Tanase, F. Benedetti, L. Makris, F. Yamashita & H.-J. Lenz. (2020) Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Annals of Oncology 31:1, pages 88-95.
Crossref
Crossref
Aneta L. Zygulska. 2019. Multidisciplinary Approach for Colorectal Cancer. Multidisciplinary Approach for Colorectal Cancer.
Yoichiro Yoshida, Takeshi Yamada, Hiroshi Matsuoka, Hiromichi Sonoda, Atsuko Fukazawa, Hiroshi Yoshida, Hideyuki Ishida, Keiji Hirata, Suguru Hasegawa, Kazuhiro Sakamoto, Toshiaki Otsuka & Keiji Koda. (2019) A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study). Journal of the Anus, Rectum and Colon 3:3, pages 136-141.
Crossref
Crossref
Muhammad Wasif Saif, Lee Rosen, Michelle A. Rudek, Weijing Sun, Dale R. Shepard, Carlos Becerra, Fumiaki Yamashita, Paul Bebeau & Robert Winkler. (2019) Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. British Journal of Clinical Pharmacology 85:6, pages 1239-1246.
Crossref
Crossref
Betty M Chan, Howard S Hochster & Heinz-Josef Lenz. (2019) The safety and efficacy of trifluridine–tipiracil for metastatic colorectal cancer: A pharmacy perspective. American Journal of Health-System Pharmacy 76:6, pages 339-348.
Crossref
Crossref
Robert J. Mayer, Howard S. Hochster, Steven J. Cohen, Robert Winkler, Lukas Makris & Axel Grothey. (2018) Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology 82:6, pages 961-969.
Crossref
Crossref
Chiara Cremolini, Daniele Rossini, Erika Martinelli, Filippo Pietrantonio, Sara Lonardi, Silvia Noventa, Emiliano Tamburini, Giovanni Luca Frassineti, Stefania Mosconi, Federico Nichetti, Sabina Murgioni, Teresa Troiani, Beatrice Borelli, Gemma Zucchelli, Alessandro Dal Maso, Vincenzo Sforza, Gianluca Masi, Carlotta Antoniotti, Maria Di Bartolomeo, Rosalba Miceli, Fortunato Ciardiello & Alfredo Falcone. (2018) Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. The Oncologist 23:10, pages 1178-1187.
Crossref
Crossref
Norihiko Suzuki, Masanobu Ito & Teiji Takechi. 2018. Successful Drug Discovery. Successful Drug Discovery
417
441
.
Kazuaki Matsuoka, Fumio Nakagawa, Takashi Kobunai & Teiji Takechi. (2018) Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression. Oncotarget 9:17, pages 13438-13450.
Crossref
Crossref
Beatrice Borelli, Gemma Zucchelli, Daniele Rossini, Chiara Cremolini, Carlotta Antoniotti, Roberto Moretto, Federica Marmorino, Camilla Colombo, Francesca Vannini, Laura Delliponti, Mario Spione, Elena Ongaro, Gianluca Masi, Isa Maura Brunetti, Elisabetta Pfanner, Lisa Salvatore & Alfredo Falcone. (2018) A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. Colorectal Cancer 7:1, pages CRC01.
Crossref
Crossref
Eric Van Cutsem, Robert J. Mayer, Stéphanie Laurent, Robert Winkler, Cristina Grávalos, Manuel Benavides, Federico Longo-Munoz, Fabienne Portales, Fortunato Ciardiello, Salvatore Siena, Kensei Yamaguchi, Kei Muro, Tadamichi Denda, Yasushi Tsuji, Lukas Makris, Patrick Loehrer, Heinz-Josef Lenz & Atsushi Ohtsu. (2018) The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. European Journal of Cancer 90, pages 63-72.
Crossref
Crossref
Vladimir A. Lisitskiy, Hamda Khan, Tatyana V. Popova, Alexey S. Chubarov, Olga D. Zakharova, Andrey E. Akulov, Oleg B. Shevelev, Evgenii L. Zavjalov, Igor V. Koptyug, Mikhail P. Moshkin, Vladimir N. Silnikov, Saheem Ahmad & Tatyana S. Godovikova. (2017) Multifunctional human serum albumin-therapeutic nucleotide conjugate with redox and pH-sensitive drug release mechanism for cancer theranostics. Bioorganic & Medicinal Chemistry Letters 27:16, pages 3925-3930.
Crossref
Crossref
Jae Ho Jeong, Yong Sang Hong & Tae Won Kim. (2017) Treatment of Refractory Colorectal Cancer: Regorafenib vs. TAS-102. Current Colorectal Cancer Reports 13:4, pages 325-333.
Crossref
Crossref
F. Longo-Muñoz, G. Argiles, J. Tabernero, A. Cervantes, C. Gravalos, C. Pericay, S. Gil-Calle, H. Mizuguchi, A. Carrato-Mena, M. L. Limón & R. Garcia-Carbonero. (2016) Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial. Clinical and Translational Oncology 19:2, pages 227-235.
Crossref
Crossref
Alberto Zaniboni, Paola Bertocchi, Sandro Barni & Fausto Petrelli. (2016) TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review. Clinical Colorectal Cancer 15:4, pages 292-297.
Crossref
Crossref
Takayuki Yoshino, Hiroyuki Uetake, Naohiro Fujita, Takaaki Furuta, Jun Katori, Naoko Hara & Kei Muro. (2016) TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study. Clinical Colorectal Cancer 15:4, pages e205-e211.
Crossref
Crossref
Giorgio Scagliotti, Makoto Nishio, Miyako Satouchi, Giuseppe Valmadre, Seiji Niho, Domenico Galetta, Diego Cortinovis, Fabio Benedetti, Eiji Yoshihara, Lukas Makris, Akira Inoue & Kaoru Kubota. (2016) A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy. Lung Cancer 100, pages 20-23.
Crossref
Crossref
Jose Mauricio Mota, Leonardo G. Fonseca, Maria Ignez Braghiroli & Paulo M. Hoff. (2016) Review on TAS-102 development and its use for metastatic colorectal cancer. Critical Reviews in Oncology/Hematology 104, pages 91-97.
Crossref
Crossref
Hideaki Bando, Toshihiko Doi, Kei Muro, Hirofumi Yasui, Tomohiro Nishina, Kensei Yamaguchi, Shunji Takahashi, Shogo Nomura, Hirofumi Kuno, Kohei Shitara, Akihiro Sato & Atsushi Ohtsu. (2016) A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). European Journal of Cancer 62, pages 46-53.
Crossref
Crossref
Daphne L. van der Velden, Frans L. Opdam & Emile E. Voest. (2016) TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies. Clinical Cancer Research 22:12, pages 2835-2839.
Crossref
Crossref
Johanna C. Bendell, Manish R. Patel, Kenichiro Yoshida, Jabed Seraj, Racquel Weaver, Charlotte Lemech, Thomas G. Todaro, Shubham Pant & Hendrik-Tobias Arkenau. (2016) Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 77:6, pages 1275-1283.
Crossref
Crossref
Saurin Chokshi & Howard S. Hochster. (2016) Single-Agent Therapies After Standard Combination Regimens. The Cancer Journal 22:3, pages 205-210.
Crossref
Crossref
Hiroyuki Kitao, Yosuke Morodomi, Shinichiro Niimi, Mamoru Kiniwa, Kazuhiko Shigeno, Kazuaki Matsuoka, Yuki Kataoka, Makoto Iimori, Eriko Tokunaga, Hiroshi Saeki, Eiji Oki & Yoshihiko Maehara. (2016) The antibodies against 5-bromo-2′-deoxyuridine specifically recognize trifluridine incorporated into DNA. Scientific Reports 6:1.
Crossref
Crossref
James J. Lee, Jabed Seraj, Kenichiro Yoshida, Hirokazu Mizuguchi, Sandra Strychor, Jillian Fiejdasz, Tyeler Faulkner, Robert A. Parise, Patrick Fawcett, Laura Pollice, Scott Mason, Jeremy Hague, Marie Croft, James Nugteren, Charles Tedder, Weijing Sun, Edward Chu & Jan Hendrik Beumer. (2016) Human mass balance study of TAS-102 using 14C analyzed by accelerator mass spectrometry. Cancer Chemotherapy and Pharmacology 77:3, pages 515-526.
Crossref
Crossref
Dominic A. SolimandoJrJr & J. Aubrey Waddell. (2016) Drug Monographs: Trabectedin and Trifluridine-Tipiracil. Hospital Pharmacy 51:2, pages 120-128.
Crossref
Crossref
Nataliya Uboha & Howard S Hochster. (2016) TAS-102: a novel antimetabolite for the 21st century. Future Oncology 12:2, pages 153-163.
Crossref
Crossref
Qiong Wei, Haijuan Liu, Honghao Zhou, Dejun Zhang, Zhiwei Zhang & Qibing Zhou. (2015) Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways. BMC Cancer 15:1.
Crossref
Crossref
Godefridus J. Peters. (2015) Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies. Therapeutic Advances in Medical Oncology 7:6, pages 340-356.
Crossref
Crossref
Heinz-Josef Lenz, Sebastian Stintzing & Fotios Loupakis. (2015) TAS-102, a novel antitumor agent: A review of the mechanism of action. Cancer Treatment Reviews 41:9, pages 777-783.
Crossref
Crossref
Johanna C. Bendell, Lee S. Rosen, Robert J. Mayer, Jonathan W. Goldman, Jeffrey R. Infante, Fabio Benedetti, Donghu Lin, Hirokazu Mizuguchi, Christopher Zergebel & Manish R. Patel. (2015) Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology 76:5, pages 925-932.
Crossref
Crossref
Toshihiko Doi, Takayuki Yoshino, Nozomu Fuse, Narikazu Boku, Kentaro Yamazaki, Wasaburo Koizumi, Ken Shimada, Yasutaka Takinishi & Atsushi Ohtsu. (2015) Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Investigational New Drugs 33:5, pages 1068-1077.
Crossref
Crossref
Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio Garcia-Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Eveline Boucher, Marc Peeters, Ben Tran, Heinz-Josef Lenz, Alberto Zaniboni, Howard Hochster, James M. Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito & Atsushi Ohtsu. (2015) Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. New England Journal of Medicine 372:20, pages 1909-1919.
Crossref
Crossref
Kazuaki Matsuoka, Makoto Iimori, Shinichiro Niimi, Hiroshi Tsukihara, Sugiko Watanabe, Shinichi Kiyonari, Mamoru Kiniwa, Koji Ando, Eriko Tokunaga, Hiroshi Saeki, Eiji Oki, Yoshihiko Maehara & Hiroyuki Kitao. (2015) Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks. Molecular Cancer Therapeutics 14:4, pages 1004-1013.
Crossref
Crossref
Ayako Doi, Kohei Shitara & Toshihiko Doi. (2014) Future Perspective of Chemotherapy for Colorectal Cancer. Nippon Daicho Komonbyo Gakkai Zasshi 67:10, pages 906-918.
Crossref
Crossref
Tatyana S. Godovikova, Vladimir A. Lisitskiy, Natalya M. Antonova, Tatyana V. Popova, Olga D. Zakharova, Alexey S. Chubarov, Igor V. Koptyug, Renad Z. Sagdeev, Robert Kaptein, Andrey E. Akulov, Vassily I. Kaledin, Valeriy P. Nikolin, Sergei I. Baiborodin, Ludmila S. Koroleva & Vladimir N. Silnikov. (2013) Ligand-Directed Acid-Sensitive Amidophosphate 5-Trifluoromethyl-2′-Deoxyuridine Conjugate as a Potential Theranostic Agent. Bioconjugate Chemistry 24:5, pages 780-795.
Crossref
Crossref
Takayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki, Tomohiro Nishina, Yoshito Komatsu, Hideo Baba, Akihito Tsuji, Kensei Yamaguchi, Kei Muro, Naotoshi Sugimoto, Yasushi Tsuji, Toshikazu Moriwaki, Taito Esaki, Chikuma Hamada, Takanori Tanase & Atsushi Ohtsu. (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. The Lancet Oncology 13:10, pages 993-1001.
Crossref
Crossref
Johan Vande Voorde, Federico Gago, Kristof Vrancken, Sandra Liekens & Jan Balzarini. (2012) Characterization of pyrimidine nucleoside phosphorylase of Mycoplasma hyorhinis: implications for the clinical efficacy of nucleoside analogues. Biochemical Journal 445:1, pages 113-123.
Crossref
Crossref
T Doi, A Ohtsu, T Yoshino, N Boku, Y Onozawa, A Fukutomi, S Hironaka, W Koizumi & T Sasaki. (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. British Journal of Cancer 107:3, pages 429-434.
Crossref
Crossref
Tomohiko Miyatani, Nobuhiro Kurita, Tohru Utsunomiya, Takashi Iwata, Masanori Nishioka, Kozo Yoshikawa, Jun Higashijima, Hideya Kashihara, Chie Takasu, Masakazu Fukushima & Mitsuo Shimada. (2012) Platelet-derived endothelial cell growth factor/thymidine phosphorylase inhibitor augments radiotherapeutic efficacy in experimental colorectal cancer. Cancer Letters 318:2, pages 199-205.
Crossref
Crossref
Johan Vande Voorde, Maurizio Quintiliani, Christopher McGuigan, Sandra Liekens & Jan Balzarini. (2012) Inhibition of pyrimidine and purine nucleoside phosphorylases by a 3,5-dichlorobenzoyl-substituted 2-deoxy-d-ribose-1-phosphate derivative. Biochemical Pharmacology 83:10, pages 1358-1363.
Crossref
Crossref
T. Okayama, K. Yoshisue, K. Kuwata, M. Komuro, S. Ohta & S. Nagayama. (2011) Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluorothymidine, a Novel Antitumor Nucleoside, in Rats. Journal of Pharmacology and Experimental Therapeutics 340:2, pages 457-462.
Crossref
Crossref